HRP20210648T1 - Amid-supstituirani derivati piridiniltriazola i njihova uporaba - Google Patents

Amid-supstituirani derivati piridiniltriazola i njihova uporaba Download PDF

Info

Publication number
HRP20210648T1
HRP20210648T1 HRP20210648TT HRP20210648T HRP20210648T1 HR P20210648 T1 HRP20210648 T1 HR P20210648T1 HR P20210648T T HRP20210648T T HR P20210648TT HR P20210648 T HRP20210648 T HR P20210648T HR P20210648 T1 HRP20210648 T1 HR P20210648T1
Authority
HR
Croatia
Prior art keywords
compound
general formula
image
formula
group
Prior art date
Application number
HRP20210648TT
Other languages
English (en)
Croatian (hr)
Inventor
Marie-Pierre Collin
Peter Kolkhof
Thomas Neubauer
Chantal FÜRSTNER
Elisabeth Pook
Matthias Beat WITTWER
Klemens Lustig
Anja BUCHMÜLLER
Hanna Tinel
Karoline DRÖBNER
Thomas MONDRITZKI
Heiko Schirmer
Axel Kretschmer
Carsten Schmeck
Pierre Wasnaire
Hana CERNECKA
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of HRP20210648T1 publication Critical patent/HRP20210648T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
HRP20210648TT 2016-05-03 2017-05-02 Amid-supstituirani derivati piridiniltriazola i njihova uporaba HRP20210648T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16168165 2016-05-03
EP17720147.2A EP3452463B1 (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof
PCT/EP2017/060356 WO2017191102A1 (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Publications (1)

Publication Number Publication Date
HRP20210648T1 true HRP20210648T1 (hr) 2021-05-28

Family

ID=55910850

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210648TT HRP20210648T1 (hr) 2016-05-03 2017-05-02 Amid-supstituirani derivati piridiniltriazola i njihova uporaba

Country Status (42)

Country Link
US (4) US9988367B2 (https=)
EP (1) EP3452463B1 (https=)
JP (1) JP6932140B2 (https=)
KR (1) KR20190003655A (https=)
CN (2) CN113121504A (https=)
AR (1) AR108262A1 (https=)
AU (1) AU2017259870B2 (https=)
BR (1) BR112018072542A2 (https=)
CA (1) CA3022749A1 (https=)
CL (1) CL2018003105A1 (https=)
CO (1) CO2018011933A2 (https=)
CR (1) CR20180522A (https=)
CU (1) CU24567B1 (https=)
CY (1) CY1124084T1 (https=)
DK (1) DK3452463T3 (https=)
DO (1) DOP2018000240A (https=)
EA (1) EA035596B1 (https=)
EC (1) ECSP18081881A (https=)
ES (1) ES2866109T3 (https=)
GE (2) GEAP202014945A (https=)
HR (1) HRP20210648T1 (https=)
HU (1) HUE053908T2 (https=)
IL (1) IL262557B (https=)
JO (1) JOP20170105B1 (https=)
LT (1) LT3452463T (https=)
MA (1) MA44851B1 (https=)
MX (1) MX381787B (https=)
NI (1) NI201800115A (https=)
PE (1) PE20190116A1 (https=)
PH (1) PH12018502268A1 (https=)
PL (1) PL3452463T3 (https=)
PT (1) PT3452463T (https=)
RS (1) RS61771B1 (https=)
SG (1) SG11201809752VA (https=)
SI (1) SI3452463T1 (https=)
SV (1) SV2018005771A (https=)
TN (1) TN2018000368A1 (https=)
TW (1) TWI772295B (https=)
UA (1) UA123791C2 (https=)
UY (1) UY37220A (https=)
WO (1) WO2017191102A1 (https=)
ZA (1) ZA201808131B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6911052B2 (ja) * 2016-05-03 2021-07-28 バイエル ファーマ アクチエンゲゼルシャフト オキソアルキル置換フェニルトリアゾール誘導体およびその使用
JOP20170103A1 (ar) * 2016-05-03 2017-11-03 Bayer Pharma AG عملية لتحضير مشتقات 1-فنيل-1، 2، 4-تريازول مستبدلة بـ 5-هيدروكسي ألكيل
CN114984003B (zh) 2016-05-03 2024-08-27 拜耳制药股份公司 芳族磺酰胺衍生物
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
US10954197B2 (en) * 2017-03-08 2021-03-23 Yogee's Bioinnovations Private Limited Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
US11149023B2 (en) 2017-10-24 2021-10-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CR20200176A (es) 2017-10-24 2020-07-24 Bayer Pharma AG Profármacos de derivados de triazol sustituido y sus usos
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
WO2019081306A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
EP3700900A1 (en) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
US20210253557A1 (en) 2017-10-24 2021-08-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
WO2019199273A1 (en) * 2018-04-10 2019-10-17 Hewlett-Packard Development Company, L.P. Preheat dyed build materials with preheating sources
KR20260018202A (ko) * 2019-12-24 2026-02-06 도쿄엘렉트론가부시키가이샤 성막 방법 및 성막 시스템
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
EP4626419A1 (en) * 2022-11-29 2025-10-08 The United States Government as represented by the Department of Veterans Affairs Eif4a1 inhibitors with antitumor activity
WO2026035773A1 (en) * 2024-08-06 2026-02-12 Retex Pharmaceuticals, Inc. Vasopressin receptor 2 modulators and methods of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP3290657B2 (ja) 1991-05-01 2002-06-10 メルク エンド カムパニー インコーポレーテッド アンギオテンシンii拮抗剤として活性な酸性アラルキルトリアゾール誘導体
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
TR200001752T2 (tr) 1997-12-17 2000-12-21 Merck & Co., Inc. Entegrin reseptör antagonistleri
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
CN1177835C (zh) 1998-07-24 2004-12-01 拜尔公司 取代的苯甲酰基环己二酮类化合物
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
AP2005003199A0 (en) 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2004221891B2 (en) 2003-03-14 2009-11-19 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin CGRP receptor antagonists
KR20060066141A (ko) 2003-06-27 2006-06-15 버글린 코퍼레이션 오브 워싱턴 사과 및 연한 코아를 가지거나 피트를 가진 다른 과일들을작은 응력을 가지고 정확하게 코아제거하고슬라이스절단하기 위한 기계
EA010132B1 (ru) * 2003-12-22 2008-06-30 Пфайзер Инк. Производные триазола в качестве антагонистов вазопрессина
EP1723117A4 (en) 2004-03-08 2009-12-02 Wyeth Corp ION CHANNEL MODULATORS
BRPI0508522A (pt) 2004-03-08 2007-08-14 Wyeth Corp moduladores de canal de ìon
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EA023221B1 (ru) * 2010-02-27 2016-05-31 Байер Интеллектуэль Проперти Гмбх СВЯЗАННЫЕ БИС-АРИЛЬНЫЕ АРИЛ-ТРИАЗОЛОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И ДВОЙНОЙ АНТАГОНИСТ V1a/V2-РЕЦЕПТОРОВ
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
MX2013003633A (es) * 2010-10-01 2013-04-24 Taisho Pharmaceutical Co Ltd Derivado de 1, 2, 4-triazolona.
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2013138860A1 (en) 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
UA121558C2 (uk) 2014-11-03 2020-06-25 Баєр Фарма Актіенгезеллшафт Гідроксіалкілзаміщені фенілтриазольні похідні та їх застосування
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
JOP20170103A1 (ar) * 2016-05-03 2017-11-03 Bayer Pharma AG عملية لتحضير مشتقات 1-فنيل-1، 2، 4-تريازول مستبدلة بـ 5-هيدروكسي ألكيل
JP6911052B2 (ja) * 2016-05-03 2021-07-28 バイエル ファーマ アクチエンゲゼルシャフト オキソアルキル置換フェニルトリアゾール誘導体およびその使用

Also Published As

Publication number Publication date
MA44851B1 (fr) 2021-09-30
EA035596B1 (ru) 2020-07-14
UY37220A (es) 2017-11-30
PH12018502268A1 (en) 2019-07-15
CY1124084T1 (el) 2022-05-27
CU20180134A7 (es) 2019-06-04
PL3452463T3 (pl) 2021-08-09
JP2019514945A (ja) 2019-06-06
BR112018072542A2 (pt) 2019-03-26
ZA201808131B (en) 2021-05-26
CL2018003105A1 (es) 2019-02-15
DOP2018000240A (es) 2019-03-15
US20190144423A1 (en) 2019-05-16
ES2866109T3 (es) 2021-10-19
US20200017473A1 (en) 2020-01-16
JP6932140B2 (ja) 2021-09-08
ECSP18081881A (es) 2018-11-30
AR108262A1 (es) 2018-08-01
EP3452463B1 (en) 2021-03-24
SV2018005771A (es) 2019-01-04
PT3452463T (pt) 2021-04-28
RS61771B1 (sr) 2021-05-31
US20180251447A1 (en) 2018-09-06
SI3452463T1 (sl) 2021-07-30
EA201892505A1 (ru) 2019-04-30
LT3452463T (lt) 2021-04-26
AU2017259870A1 (en) 2018-11-15
TW201806941A (zh) 2018-03-01
EP3452463A1 (en) 2019-03-13
GEP20207158B (en) 2020-10-12
MX2018013335A (es) 2019-05-09
SG11201809752VA (en) 2018-12-28
CR20180522A (es) 2019-01-15
GEAP202014945A (en) 2020-05-11
CN113121504A (zh) 2021-07-16
TWI772295B (zh) 2022-08-01
WO2017191102A1 (en) 2017-11-09
PE20190116A1 (es) 2019-01-16
HUE053908T2 (hu) 2021-07-28
DK3452463T3 (da) 2021-04-26
UA123791C2 (uk) 2021-06-02
US9988367B2 (en) 2018-06-05
CU24567B1 (es) 2022-01-13
CA3022749A1 (en) 2017-11-09
CN109415347A (zh) 2019-03-01
US10472348B2 (en) 2019-11-12
MA44851A (fr) 2019-03-13
IL262557A (en) 2018-12-31
IL262557B (en) 2022-01-01
KR20190003655A (ko) 2019-01-09
AU2017259870B2 (en) 2021-07-15
US11091463B2 (en) 2021-08-17
US20170320854A1 (en) 2017-11-09
CO2018011933A2 (es) 2018-11-22
JOP20170105B1 (ar) 2022-03-15
CN109415347B (zh) 2021-05-07
MX381787B (es) 2025-03-13
NI201800115A (es) 2019-03-14
TN2018000368A1 (en) 2020-06-15

Similar Documents

Publication Publication Date Title
HRP20210648T1 (hr) Amid-supstituirani derivati piridiniltriazola i njihova uporaba
JP2019514945A5 (https=)
JP4463317B2 (ja) 置換イミダゾールおよび殺虫剤としてのその使用
EP0908456B1 (de) Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
Neely et al. Pyridine synthesis by [4+ 2] cycloadditions of 1-azadienes: hetero-Diels Alder and transition metal-catalysed approaches
DE19744027A1 (de) Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln
JP6591530B2 (ja) 有機化合物
HUE025162T2 (en) THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc)
ME02809B (me) Ariltriazoloni spojeni sa bis-arilom i njihova upotreba
MA43668B1 (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
JP2012509877A5 (https=)
PT89400A (pt) Processo para a preparacao de novos compostos heterociclicos substituidos comportando um nucleo pirrolico, pirazolico ou triazolico e de composicoes farmaceuticas que os contem
JP2012509877A (ja) 可溶性グアニレートシクラーゼ活性化剤
WO2011161099A1 (de) Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
DE10216145A1 (de) Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
HU198045B (en) Process for production of derivatives of 5-(6-imidazo-/1,2-a/-piridil)-piridin and medical preparatives containing these compounds as active substance
EA010740B1 (ru) Замещенные арилпиразолы в качестве противопаразитарных средств
Yusubov et al. Synthesis of unsymmetrical hetaryl-1, 2-diketones
FI61489C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 6-arylpyrrolo(1,2-a)imidatzolderivat
DE60216610T2 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
CH636615A5 (en) Pharmaceutically effective, optionally substituted imidazo(1,5-d)-as-triazin-4-(3H)-ones and -thiones
DE69011046T2 (de) Pyridinderivate, Verfahren zur Herstellung und pharmazeutische Zusammensetzungen.
WO2014027112A1 (de) Tris-(hetero)aryl-pyrazole und ihre verwendung
DE19807423A1 (de) Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln
CN104610267A (zh) 无催化条件下高效的合成6-烷基吡唑并[1,5-c]喹唑啉骨架化合物的方法